Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
27 "Nan Hee Kim"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Diabetes, obesity and metabolism
Big Data Articles (National Health Insurance Service Database)
A Nomogram for End-Stage Renal Disease Prediction in Patients with Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea
Inha Jung, Bong-Seong Kim, So Young Park, Da Young Lee, Ji Hee Yu, Ji A Seo, Kyung-Do Han, Nan Hee Kim
Endocrinol Metab. 2026;41(2):245-255.   Published online November 12, 2025
DOI: https://doi.org/10.3803/EnM.2025.2570
  • 3,639 View
  • 95 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Despite the rising incidence of end-stage renal disease (ESRD) among individuals with type 2 diabetes mellitus (T2DM) in Korea, no predictive model or nomogram has been developed using a nationwide cohort. In this study, we developed a nomogram to predict the long-term risk of ESRD in patients with T2DM using a large-scale, population-based Korean database.
Methods
Using the Korean National Health Insurance Database, patients with T2DM who underwent health examinations between 2015 and 2016 were assigned as development (n=1,744,277) and validation (n=747,407) cohorts. New ESRD cases were identified using codes for renal replacement therapy. A Cox proportional hazards regression model was used to derive a risk-scoring system, and 13 variables were selected. A risk score nomogram was then created to estimate the risk of ESRD.
Results
In the development cohort, 8,631 patients with T2DM developed ESRD during a follow-up period of 4.8±0.9 years. After multivariable adjustment, significant predictors of ESRD included male sex, current smoking, physical inactivity, low income, low body mass index, hypertension, low-density lipoprotein cholesterol ≥160 mg/dL, chronic kidney disease, insulin use, and longer duration of T2DM. A final nomogram incorporating 13 variables was developed to estimate the individual probability of ESRD. The concordance index for ESRD prediction in the validation cohort was 0.906 (95% confidence interval, 0.9 to 0.912).
Conclusion
This 13-variable nomogram provides a simple tool for identifying patients with T2DM at high risk of ESRD and may aid in early intervention.
Close layer
Thyroid
Big Data Articles (National Health Insurance Service Database)
Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea
Jung A Kim, Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Endocrinol Metab. 2025;40(1):125-134.   Published online January 13, 2025
DOI: https://doi.org/10.3803/EnM.2024.2093
  • 7,043 View
  • 170 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Antithyroid drug (ATD) treatment is the preferred initial treatment for Graves’ disease (GD) in South Korea, despite higher treatment failure rates than radioactive iodine (RAI) therapy or thyroidectomy. This study aimed to evaluate the incidence of treatment failure associated with the primary modalities for GD treatment in real-world practice.
Methods
We included 452,001 patients diagnosed with GD between 2004 and 2020 from the Korean National Health Insurance Service-National Health Information Database. Treatment failure was defined as switching from ATD, RAI, or thyroidectomy treatments, and for ATD specifically, inability to discontinue medication for over 2 years.
Results
Mean age was 46.2 years, with females constituting 70.8%. Initial treatments for GD included ATDs (98.0%), thyroidectomy (1.3%), and RAI (0.7%), with a noted increment in ATD application from 96.2% in 2004 to 98.8% in 2020. During a median follow- up of 8.5 years, the treatment failure rates were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Multivariate analysis indicated that the hazard ratio for treatment failure with ATD was 2.81 times higher than RAI. RAI treatments ≥10 mCi had 37% lower failure rates than doses <10 mCi.
Conclusion
ATDs are the most commonly used for GD in South Korea, followed by thyroidectomy and RAI. Although the risk of treatment failure for ATD is higher than that of RAI therapy, initial RAI treatment in South Korea is relatively limited compared to that in Western countries. Further studies are required to evaluate the cause of low initial RAI treatment rates in South Korea.

Citations

Citations to this article as recorded by  
  • Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions
    Sun Wook Cho, Jung Hee Kim, Kyoung Jin Kim, Beom-Jun Kim, Mee Kyoung Kim, Eun Jung Rhee
    Endocrinology and Metabolism.2026; 41(1): 86.     CrossRef
  • Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
    Chan-Hee Jung
    Endocrinology and Metabolism.2025; 40(1): 70.     CrossRef
  • Process to radioactive iodine treatment for Graves’ hyperthyroidism: condemned or absolved?
    Luigi Bartalena, Daniela Gallo, George J. Kahaly, Eliana Piantanida, Maria Laura Tanda
    Journal of Endocrinological Investigation.2025; 48(9): 1927.     CrossRef
Close layer
Diabetes, obesity and metabolism
Impact of Chronic Kidney Disease and Gout on End-Stage Renal Disease in Type 2 Diabetes: Population-Based Cohort Study
Inha Jung, Da Young Lee, Seung Min Chung, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A Seo, Kyungdo Han, Nan Hee Kim
Endocrinol Metab. 2024;39(5):748-757.   Published online August 30, 2024
DOI: https://doi.org/10.3803/EnM.2024.2020
  • 9,747 View
  • 109 Download
  • 8 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We examined the impact of gout on the end-stage renal disease (ESRD) risk in patients with type 2 diabetes mellitus (T2DM) and determined whether this association differs according to chronic kidney disease (CKD) status.
Methods
Using the Korean National Health Insurance Service, this nationwide cohort study enrolled 847,884 patients with T2DM who underwent health checkups in 2009. Based on the presence of CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2) and gout (two outpatient visits or one hospitalization within 5 years), patients were classified into four groups: CKD−Gout−, CKD− Gout+, CKD+Gout−, and CKD+Gout+. Patients with incident ESRD were followed up until December 2018.
Results
Among 847,884 patients, 11,825 (1.4%) experienced progression to ESRD. ESRD incidence increased in the following order: 0.77 per 1,000 person-years (PY) in the CKD−Gout− group, 1.34/1,000 PY in the CKD−Gout+ group, 8.20/1,000 PY in the CKD+Gout− group, and 23.06/1,000 PY in the CKD+Gout+ group. The presence of gout modified the ESRD risk in a status-dependent manner. Hazard ratios (HR) were 1.49 (95% confidence interval [CI], 1.32 to 1.69) and 2.24 (95% CI, 2.09 to 2.40) in patients without and with CKD, respectively, indicating a significant interaction (P<0.0001). The CKD+Gout+ group had a markedly higher risk of developing ESRD (HR, 18.9; 95% CI, 17.58 to 20.32) than the reference group (CKD−Gout−).
Conclusion
Gout substantially enhances the risk of ESRD, even in the absence of CKD. Concurrent CKD and gout synergistically increase the risk of ESRD. Therefore, physicians should carefully screen for hyperuricemia to prevent progression to ESRD.

Citations

Citations to this article as recorded by  
  • Undescribed phenylspirodrimane dimers with anti-gouty activity from the coral-derived fungus Stachybotrys chartarum
    Shuang Lin, Yi-Fan Geng, Hanxiao Zeng, Zixue Chai, Baolei Fan, Jun-Cheng Su, Yonghui Zhang, Zhengxi Hu
    Phytochemistry.2026; 248: 114891.     CrossRef
  • Gout in the era of multimorbidity: pathogenesis, systemic comorbidities, and evolving therapeutic strategies
    Phillip J Kim, Jihun Kang, Jesang Yu, Geun-Tae Kim, Yunkyung Kim
    Kosin Medical Journal.2026; 41(1): 26.     CrossRef
  • Acute gout attack in a peritoneal dialysis patient treated with Firsekibart: a case report
    Wenqian Wei, Lijie Gu, Hanyu Meng, Nan Zhu, Shu Rong
    Open Medicine.2026;[Epub]     CrossRef
  • Polydatin alleviates adenine-induced nephropathy in mice
    Tao Sheng, Tianhong Ma, Xin Jin, Debin Chen, Shipeng Che, Jie Wang, Jiadu Shen, Chaoqun Shi, Qiang Li, Yixin Sun, Deqing Chen, Guangtao Xu
    Renal Failure.2026;[Epub]     CrossRef
  • Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus
    Qian Zhang, Jing Xu, Yanying Qian
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • ปัจจัยที่สัมพันธ์กับระดับความเสี่ยงโรคไตเรื้อรังตามเกณฑ์ KDIGO ในผู้ป่วยโรคเบาหวานชนิดที่ 2 ในประเทศไทย: การวิเคราะห์ข้อมูลทุติยภูมิ ด้วยการถดถอยโลจิสติกเชิงอันดับ
    สมฤทัย ไชยอักษร, ปราถนา สถิตย์วิภาวี, จุฑาธิป ศีลบุตร, ชูเกียรติ วิวัฒน์วงศ์เกษม, ราม รังสินธุ์
    Thai Red Cross Nursing Journal.2026; 19(2): 18.     CrossRef
  • Development and validation of a risk models for gout in patients with diabetic kidney disease
    Ningyu Cai, Mengdie Chen, Yiyun Wang, Ping Feng, Xianping Zhu, Qidong Zheng
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • СУЧАСНІ СТРАТЕГІЇ МЕНЕДЖМЕНТУ ГІПЕРУРИКЕМІЇ, ПОДАГРИ ТА КОМОРБІДНИХ СТАНІВ: АНАЛІЗ МІЖНАРОДНИХ ПРОТОКОЛІВ, НОВІТНІХ ТЕРАПЕВТИЧНИХ МІШЕНЕЙ ТА ПЕРСОНАЛІЗОВАНОЇ ТЕРАПІЇ
    В.М. Ждан, В.Г. Лебідь, М.Ю. Бабаніна, О.А. Кир’ян, Г.В. Волченко, Є.М. Кітура, І.В. Іваницький, М.В. Ткаченко
    Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2026; 26(3): 322.     CrossRef
  • Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants
    Andrea O. Y. Luk, Yingnan Fan, Baoqi Fan, Edith W. K. Chow, Tony C. K. O
    Diabetologia.2025; 68(11): 2386.     CrossRef
  • Relationship between the Chinese visceral adiposity index and gout in individuals with type 2 diabetes mellitus: a cross-sectional population-based study
    Ningyu Cai, Mengdie Chen, Ping Feng, Yiyun Wang, Xianping Zhu, Qidong Zheng
    Frontiers in Nutrition.2025;[Epub]     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinol Metab. 2023;38(1):43-55.   Published online February 27, 2023
DOI: https://doi.org/10.3803/EnM.2022.1629
  • 27,465 View
  • 1,490 Download
  • 42 Web of Science
  • 47 Crossref
AbstractAbstract PDFPubReader   ePub   
Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of diabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosterone system inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option to delay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.

Citations

Citations to this article as recorded by  
  • Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease
    Kai Chen, Wei Shao, Huaxiong Zhang
    Medicine.2026; 105(4): e47098.     CrossRef
  • Efficacy and Safety of Finerenone in Patients with Idiopathic Membranous Nephropathy: A Multicentre, Prospective-Retrospective Real-World Study
    Jia-Yi Li, Yu-Lin Zhu, Jian-Peng Zhang, Jia-Mei Lu, Xiao-Yong Yu, Jing E, Yang Wei, Dan-Na Ma, Akhmedova Nilufar Sharipovna, Jason Choo, Chieh Suai Tan, Min Qi, Yan Li, Xiao-tao Ma, Zhe Kang, Zhao Chen, Xiang-hui Chen, Rong-Guo Fu
    American Journal of Nephrology.2026; : 1.     CrossRef
  • Finrenone and sodium-glucose cotransporter 2 inhibitor polypill: how “CONFIDENT” are we?
    Gerry George Mathew
    Kidney Research and Clinical Practice.2026; 45(2): 286.     CrossRef
  • Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study
    Xu-Ying Liu, Ya-Min Zhao, Ya-Guang Zhang, Yi Liu, Bo-Ya Wang, Zhen-Zhen Hao, Man-Hui Hu
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
    Amy K. Mottl, Deirdre L. Sawinski, Petter Bjornstad
    American Journal of Kidney Diseases.2026; 87(5): 730.     CrossRef
  • Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
    Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu
    Diabetes, Obesity and Metabolism.2026; 28(5): 3568.     CrossRef
  • Cardiovascular risk in primary aldosteronism: inflammatory drivers, residual risk, and emerging combination strategies
    Haoze Liu, Zejun Wu, Xinzhe Liu, Yuyuan Hu, Kaixuan Zhang, Jiwen Shang
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
    Qing Yang, Lijun Zhao, Jing Ma, Shuming Ji, Duolao Wang, Jing Li, Sheyu Li, Fang Liu
    Diabetes, Obesity and Metabolism.2026; 28(7): 6225.     CrossRef
  • Finerenone: features of action, current evidence base and examples of clinical application
    A. D. Erlikh, E. V. Bublik, A. V. Zilov, O. S. Lebedeva, A. G. Farmanov, D. Y. Shchekochikhin
    Diabetes mellitus.2026; 29(2): 215.     CrossRef
  • Finerenone exposure and ischaemic stroke in patients with type 2 diabetes and chronic kidney disease: A propensity score-matched cohort study
    Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang
    Clinical Medicine.2026; 26(5): 100617.     CrossRef
  • Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort
    Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, Serpil Müge Değer, Mustafa Demir, Sümeyra Koyuncu, Üstün Yılmaz, Ayça İnci, Hülya Çolak, Bülent Demirel
    Clinical Kidney Journal.2026;[Epub]     CrossRef
  • Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study
    Juan Pei, Xuejuan Sun, Xiuhua Xu, Peijin Bai, Ruihong Huang, Jun Zhang, Xing Chen, Lijing Yao, Leping Shao, Yinan Li
    Renal Failure.2026;[Epub]     CrossRef
  • Signaling pathways in the pathogenesis of diabetic kidney disease (review)
    O. A. Nagibovich, A. L. Kovalenko, O. S. Ketlinskaya
    Nephrology (Saint-Petersburg).2026; 30(3): 18.     CrossRef
  • GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
    Jan Boeckhaus, John A. Sayer, Holly Mabillard
    Clinical Science.2026; 140(10): 2249.     CrossRef
  • Short-term superiority in proteinuria control with exploratory longitudinal trajectories: finerenone-dapagliflozin combination in non-diabetic kidney disease
    Mali Zhu, Yingyi Deng, Lijun Su, Haixia Zhang, Yun Yang, Lulu Wang
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
    Merita Rroji, Goce Spasovski
    PROTEOMICS.2025;[Epub]     CrossRef
  • Finerenona no Tratamento da Nefropatia Diabética: Perspectivas Atuais e Evidências Clínicas
    Rosana Maciel Schmidt, Luis Alberto Batista Peres, Alfredo Casagrande Laude
    Cuadernos de Educación y Desarrollo.2025; 17(3): e7760.     CrossRef
  • Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
    Yu Sun, Mingzhu Wang
    International Urology and Nephrology.2025; 57(8): 2567.     CrossRef
  • Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM
    Shadi Bazzazzadehgan, Zia Shariat-Madar, Fakhri Mahdi
    Biomolecules.2025; 15(3): 414.     CrossRef
  • Renal function trajectories of Japanese adults with diabetic kidney disease on different diet therapies including energy-restricted and low-carbohydrate diets: a retrospective cohort study
    Tomomi Shirai, Sakiko Inaba, Miyu Maemura, Maki Saho, Miyu Sato, Mariko Sanada, Yoko Tsukamoto, Gaku Inoue, Taichi Nagahisa, Shinichi Tanaka, Hajime Tanaka, Hideaki Kurata, Takeshi Katsuki, Toshihide Kawai, Satoru Yamada
    Diabetology International.2025; 16(3): 493.     CrossRef
  • Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy
    Lingli Ma, Dianyuan Liu, Yue Yu, Zimeng Li, Qing Wang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Finerenone’s safety and efficacy in membranous nephropathy: an emerging perspective
    Aqsa Afzal, Ayesha Fatima, Ayesha Abdul Razzaq
    International Urology and Nephrology.2025; 57(10): 3479.     CrossRef
  • A Novel Therapy of Finerenone and Dapagliflozin for Lipoprotein Glomerulopathy
    Haowen Lin, Yuhe Yin, Jianchao Ma, Shuangxin Liu
    Kidney International Reports.2025; 10(10): 3696.     CrossRef
  • Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial
    Zhaojie Song, Haibao Xu, Jiaheng Zhang, Yezhou Liu, Chao Li, Tao Chen, Sujuan Guo, Ni Zhu
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease
    Eleni Hughes, Xiaoxin X. Wang, Lily Sabol, Keely Barton, Sujit Hegde, Komuraiah Myakala, Ewa Krawczyk, Avi Rosenberg, Moshe Levi
    American Journal of Physiology-Renal Physiology.2025; 329(4): F510.     CrossRef
  • Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies
    Yi Lv, Chen Ye, Zixi Li, Jiajia Ye, Huanhuan Cao, Chun Zhang, Huajun Jiang, Yumei Wang
    Diabetes/Metabolism Research and Reviews.2025;[Epub]     CrossRef
  • Nephroprotective activity of naringenin in gentamicin-induced nephrotoxicity in male Wistar rats: In-vivo and in-silico evaluation
    William Bwambale, Victor Otu Oka, Ekom Monday Etukudo, Daniel Udofia Owu, Etah Etah Nkanu, Idara Asuquo Okon, Saali Dembe Emmanuel, Umar Uthman Shehu, Ntoni Wilber, Allan Kambere, Richard Arinaitwe, Venesio Bwambale
    Pharmacological Research - Natural Products.2025; 9: 100406.     CrossRef
  • The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
    Komuraiah Myakala, Xiaoxin X. Wang, Nataliia Shults, Eleni P. Hughes, Patricia de Carvalho Ribeiro, Rozhin Penjweini, Katie Link, Keely Barton, Ewa Krawczyk, Cheryl Clarkson Paredes, Anastas Popratiloff, Jay R. Knutson, Ashley L. Cowart, Moshe Levi
    American Journal of Physiology-Renal Physiology.2025; 329(5): F724.     CrossRef
  • Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
    Xue-Dong An, Xin-Qin Li, He Zhang, Qian-You Jia, Yue-Hong Zhang, Gui-Gui Yang
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
    Markus van der Giet
    CardioVasc.2024; 24(1): 33.     CrossRef
  • Chicoric acid advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway
    Weiwei Zhang, Yong Liu, Jiajun Zhou, Teng Qiu, Haitang Xie, Zhichen Pu
    Clinical and Experimental Hypertension.2024;[Epub]     CrossRef
  • Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease
    Siyuan Cui, Xin Chen, Jiayu Li, Wei Wang, Deqi Meng, Shenglong Zhu, Shiwei Shen
    Cell Communication and Signaling.2024;[Epub]     CrossRef
  • Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
    Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi
    International Journal of Molecular Sciences.2024; 25(7): 3969.     CrossRef
  • Rediscovery of the Implication of Albuminuria in Heart Failure: Emerging Classic Index for Cardiorenal Interaction
    Kyung-Duk Min, Yuki Matsumoto, Masanori Asakura, Masaharu Ishihara
    ESC Heart Failure.2024; 11(6): 3470.     CrossRef
  • Decoding the role of aldosterone in glycation-induced diabetic complications
    Mayura Apte, Saee Zambre, Pratiksha Pisar, Bishnudeo Roy, Rashmi Tupe
    Biochemical and Biophysical Research Communications.2024; 721: 150107.     CrossRef
  • Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier
    Ayesha Maryam, Muhammad Salman Nadeem, Ayesha Fatima, Kashaf Noor Asmat
    International Urology and Nephrology.2024; 57(1): 295.     CrossRef
  • A new perspective on proteinuria and drug therapy for diabetic kidney disease
    Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, Zheyi Dong
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Molecular Therapeutics for Diabetic Kidney Disease: An Update
    Man Guo, Fangfang He, Chun Zhang
    International Journal of Molecular Sciences.2024; 25(18): 10051.     CrossRef
  • Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats
    Tham Thi Bui, So-Hyeon Kim, Woojin Jung, Sung-yoon Yang, Quyen Thi Tran, Hyunjung Lee, Seongwon Park, Lien Thi Ngo, Hwi-yeol Yun, Jung-woo CHAE
    European Journal of Drug Metabolism and Pharmacokinetics.2024; 49(6): 701.     CrossRef
  • A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
    Shuhui Zhai, Baisheng Ma, Weiwei Chen, Qini Zhao
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • Exercise as a therapeutic approach to alleviate diabetic kidney disease: mechanisms, clinical evidence and potential exercise prescriptions
    Rao Fan, Jianda Kong, Jiahao Zhang, Lei Zhu
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
    Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi
    Kidney and Blood Pressure Research.2024; 49(1): 1041.     CrossRef
  • Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
    Akshyaya Pradhan, Umesh Chandra Tripathi
    The Egyptian Heart Journal.2024;[Epub]     CrossRef
  • The Impact of Finerenone on Changes in Pulse Wave Velocity, Arterial Pressure and Heart Related Deaths in Hemodialysis Patients&#8212;Study Perspective
    Ljiljana Fodor Duric, Bozidar Vujicic, Tonko Gulin, Matko Gulin
    Open Journal of Nephrology.2024; 14(02): 216.     CrossRef
  • Epigenetic modification in diabetic kidney disease
    Zhe Liu, Jiahui Liu, Wanning Wang, Xingna An, Ling Luo, Dehai Yu, Weixia Sun
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
    Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
    Biomedicines.2023; 11(10): 2828.     CrossRef
  • Finerenone and other future therapeutic options for Alport syndrome
    Helen Pearce, Holly Mabillard
    Journal of Rare Diseases.2023;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Sleep Duration and the Risk of Type 2 Diabetes: A Community-Based Cohort Study with a 16-Year Follow-up
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Seung Ku Lee, Chol Shin, Nan Hee Kim
Endocrinol Metab. 2023;38(1):146-155.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1582
  • 15,770 View
  • 367 Download
  • 18 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
We aimed to investigate the moderating effects of obesity, age, and sex on the association between sleep duration and the development of diabetes in Asians.
Methods
We analyzed data from a cohort of the Korean Genome and Epidemiology Study conducted from 2001 to 2020. After excluding shift workers and those with diabetes at baseline, 7,407 participants were stratified into three groups according to sleep duration: ≤5 hours/night, >5 to 7 hours/night (reference), and >7 hours/night. The Cox proportional hazards analyses were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes mellitus (T2DM). Subgroup analyses were performed according to obesity, age, and sex.
Results
During 16 years of follow-up, 2,024 cases of T2DM were identified. Individuals who slept ≤5 h/night had a higher risk of incident diabetes than the reference group (HR, 1.17; 95% CI, 1.02 to 1.33). The subgroup analysis observed a valid interaction with sleep duration only for obesity. A higher risk of T2DM was observed in the ≤5 hours/night group in non-obese individuals, men, and those aged <60 years, and in the >7 hours/night group in obese individuals (HRs were 1.34 [95% CI, 1.11 to 1.61], 1.22 [95% CI, 1 to 1.49], and 1.18 [95% CI, 1.01 to 1.39], respectively).
Conclusion
This study confirmed the effect of sleep deprivation on the risk of T2DM throughout the 16-year follow-up period. This impact was confined to non-obese or young individuals and men. We observed a significant interaction between sleep duration and obesity.

Citations

Citations to this article as recorded by  
  • Glucose homeostasis during recurrent periods of sleep restriction and recovery in healthy young adults
    Yuki Y Y Cheung, Torance Y L Tan, Tiffany B Koa, Chin Meng Khoo, June C Lo
    SLEEPJ.2026;[Epub]     CrossRef
  • Mobile Phone Addiction and Sleep Quality Among Children and Adolescents: Unraveling the Health Consequences
    Ghizal Fatima, Vani Shukla, Aminat Magomedova, Rasul Magomedov
    Cureus.2026;[Epub]     CrossRef
  • Association of daytime circadian-aligned activity with glycemic control in type 2 diabetes: Insights from continuous glucose monitoring and wearable data
    Da Young Lee, Jung-Been Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Heon-Jeong Lee, Nan Hee Kim
    Metabolism.2026; 179: 156570.     CrossRef
  • The Role of Circadian Rhythm Dysregulation, Abnormal Sleep Patterns, and Sleep Disorders on the Development of Diabetes
    Hulya Merie, Bashair M. Mussa, Salah Abusnana
    Clocks & Sleep.2026; 8(2): 22.     CrossRef
  • Body-weight-specific and shared metabolomic responses to acute sleep loss in young adults
    Linnéa Good, Luiz Eduardo Mateus Brandão, Lieve Thecla van Egmond, Payam Emami Khoonsari, Ida Erngren, Henrik Carlsson, Robert Fredriksson, Kim Kultima, Christian Benedict, Jonathan Cedernaes
    Journal of Translational Medicine.2026;[Epub]     CrossRef
  • Association Between Sleep Duration and Glycemic Levels in Adults With Prediabetes: A Population-based Study
    Zhongqing Mou, Yan Zhou, Zaiquan Dong
    Canadian Journal of Diabetes.2026;[Epub]     CrossRef
  • Sleep features and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis
    Hongyi Liu, Hui Zhu, Qinkang Lu, Wen Ye, Tao Huang, Yuqiong Li, Bingqi Li, Yingxin Wu, Penghao Wang, Tao Chen, Jin Xu, Lindan Ji
    Annals of Medicine.2025;[Epub]     CrossRef
  • The potential impact of habitual sleep quality on glycaemic control and inflammation: A study on geriatric patients recently diagnosed with type 2 diabetes mellitus (T2DM)
    Nadia Hussain, Amal Hussain Ibrahim Al Haddad, Saima Abbass, Zina Alfahl
    Sleep Medicine: X.2025; 9: 100139.     CrossRef
  • The link between sleep duration and stroke risk
    Yu Cheng, Yuchuan Ding, Ahmed Elmadhoun, Xunming Ji, Xiaokun Geng
    Brain Circulation.2025; 11(1): 1.     CrossRef
  • Association between obstructive sleep apnea risk and atherosclerosis: A nationwide cross-sectional study in the Korean population
    Il Rae Park, Yong Geun Chung, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Qian Wu
    PLOS One.2025; 20(5): e0322897.     CrossRef
  • Case Report on the Improvement of Uncontrolled Blood Glucose with Shihogayonggolmoryo-tang, Yeonggyechulgam-tang, and Korean Medicine Complex Therapy
    Nahyun Cho, Chul-woo Ahn, Hyungsun Jun, Hyun-jong Jung, Dasol Park, Jungtae Leem
    The Journal of Internal Korean Medicine.2025; 46(3): 511.     CrossRef
  • The relationship between sleep patterns and the risk of edentulism: evidence from the CHARLS
    Hong-Yu Zhao, Peng-Lu Jia, Ping Ma, Wu-Long Jin, Hua-Jiao Yu
    Postgraduate Medical Journal.2025; 102(1203): 48.     CrossRef
  • Impact of Technological Advances on Type 2 Diabetes and Its Effect on Mental Health: A Perspective
    Varun Damle, Ankit Halder, Tanvi Damle
    Annals of Indian Psychiatry.2025;[Epub]     CrossRef
  • Reinterpreting Yangsaeng in Physiology on Korean Medicine for Geriatric Care: A Personalized Self-Care Model for Future Medicine
    Su Jin Lee, Young-Kyu Kwon
    Journal of Physiology & Pathology in Korean Medicine.2025; 39(6): 271.     CrossRef
  • Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
    Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(1): 37.     CrossRef
  • Role of Sleep and Sleep Disorders in Cardiometabolic Risk: a Review and Update
    Shaden O. Qasrawi, Ahmed S. BaHammam
    Current Sleep Medicine Reports.2024; 10(1): 34.     CrossRef
  • Evaluating reliability in wearable devices for sleep staging
    Vera Birrer, Mohamed Elgendi, Olivier Lambercy, Carlo Menon
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Replication Study of Genome Wide Association Study of Sleep Duration in Korean Association Resources Cohort
    Seok-Ho Cho, Seon-Ah Kim, Hyun-Seok Jin, Hong Sung Kim
    Biomedical Science Letters.2024; 30(2): 86.     CrossRef
  • Insights into optimal BMI from the GlasVEGAS study
    Chun-Kwan O, Juliana C. N. Chan
    Nature Metabolism.2024; 6(8): 1435.     CrossRef
  • Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer’s disease in elderly
    Upasana Mukherjee, Ujala Sehar, Malcolm Brownell, P. Hemachandra Reddy
    Ageing Research Reviews.2024; 100: 102457.     CrossRef
  • The Relationship Between the Risk of Type 2 Diabetes and Insomnia Severity and Sleep Duration in Academicians
    Tuğba Bilgehan, Esra Çalık Var
    Sağlık Bilimleri Üniversitesi Hemşirelik Dergisi.2024; 6(3): 203.     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The Link Between Sleeping and Type 2 Diabetes: A Systematic Review
    Ali Darraj
    Cureus.2023;[Epub]     CrossRef
Close layer
Clinical Study
Impact of the Dynamic Change of Metabolic Health Status on the Incident Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Jung A Kim, Da Hye Kim, Seon Mee Kim, Yong Gyu Park, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi, Kyungdo Han, Hye Jin Yoo
Endocrinol Metab. 2019;34(4):406-414.   Published online December 23, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.4.406
  • 12,140 View
  • 100 Download
  • 24 Web of Science
  • 28 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Metabolically healthy obese (MHO) is regarded as a transient concept. We examined the effect of the dynamic change of metabolic health status on the incidence of type 2 diabetes mellitus (T2DM) both in obese and normal weight individuals.

Methods

We analyzed 3,479,514 metabolically healthy subjects aged over 20 years from the Korean National Health Screening Program, who underwent health examination between 2009 and 2010, with a follow-up after 4 years. The relative risk for T2DM incidence until the December 2017 was compared among the four groups: stable metabolically healthy normal weight (MHNW), unstable MHNW, stable MHO, and unstable MHO.

Results

During the 4 years, 11.1% of subjects in the MHNW group, and 31.5% in the MHO group converted to a metabolically unhealthy phenotype. In the multivariate adjusted model, the unstable MHO group showed the highest risk of T2DM (hazard ratio [HR], 4.67; 95% confidence interval [CI], 4.58 to 4.77). The unstable MHNW group had a higher risk of T2DM than stable MHO group ([HR, 3.23; 95% CI, 3.16 to 3.30] vs. [HR, 1.81; 95% CI, 1.76 to 1.85]). The stable MHO group showed a higher risk of T2DM than the stable MHNW group. The influence of the transition into a metabolically unhealthy phenotype on T2DM incidence was greater in subjects with aged <65 years, women, and those with weight gain.

Conclusion

Metabolically healthy phenotype was transient both in normal weight and obese individuals. Maintaining metabolic health was critical for the prevention of T2DM, irrespective of their baseline body mass index.

Citations

Citations to this article as recorded by  
  • Association between albumin-bilirubin (ALBI) score and metabolically healthy obesity among US adults: findings from NHANES 2005–2018
    Chenyi Ji, Fang Liu
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • Metabolic health phenotypes and cardiovascular disease among U.S. adults with central obesity: Evidence from NHANES 2011– March 2020
    David Kweku Aseda Donkor, Emmanuel Amoako Agyei, Samuel Prince Osei, Frederick Frimpong Opuni, Evelyn Gyau-Boakye, Maxwell Emmie, Adwoa Benyiwah Amoah, Sandra Agyenim Boateng, Dennis Dela Tsagli, Eunice Akomaning
    Obesity Pillars.2026; 18: 100267.     CrossRef
  • Dynamic Changes in Metabolic Syndrome Severity Score and Its Components with Risk of Type 2 Diabetes Mellitus: Insights from Joint Longitudinal and Survival Modeling
    Safdar Masoumi, Ebrahim Hajizadeh, Farzad Eskandari, Davood Khalili
    Metabolic Syndrome and Related Disorders.2026; 24(6): 258.     CrossRef
  • Sex-stratified associations of TyG index and HOMA-IR changes with incident type 2 diabetes
    Sojin Kim, Sujeong Shin, Yoosoo Chang, Eunju Sung, Jae-Heon Kang
    Scientific Reports.2026;[Epub]     CrossRef
  • Metabolic health, independent of body mass index, is associated with mortality risk in type 1 diabetes
    Jung A Kim, Jimi Choi, Kyeong Jin Kim, Soo Myoung Shin, Young‐Eun Kim, Kyoung Jin Kim, Hee Young Kim, Nam Hoon Kim, Sin Gon Kim
    Journal of Diabetes Investigation.2026;[Epub]     CrossRef
  • Association of obesity phenotypes with risk of cardiovascular disease mortality: a prospective cohort study
    Ruixue Song, Yanfeng Jiang, Jiaojiao Pang, Shuo Wu, Jingjing Ma, Ping Li, Xiaohui Wu, Feng Xu, Jiali Wang, Xingdong Chen, Yuguo Chen
    BMC Public Health.2025;[Epub]     CrossRef
  • Dynamic Changes in Metabolic Status Are Associated With Risk of Ocular Motor Cranial Nerve Palsies
    Daye Diana Choi, Kyung-Ah Park, Kyungdo Han, Sei Yeul Oh
    Journal of Neuro-Ophthalmology.2024; 44(3): 386.     CrossRef
  • Metabolically healthy obese individuals are still at high risk for diabetes: Application of the marginal structural model
    Hye Ah Lee, Hyesook Park
    Diabetes, Obesity and Metabolism.2024; 26(2): 431.     CrossRef
  • The prevalence of metabolically healthy obesity and its transition into the unhealthy state: A 5‐year follow‐up study
    Amir Baniasad, Mohammad Javad Najafzadeh, Hamid Najafipour, Mohammad Hossein Gozashti
    Clinical Obesity.2024;[Epub]     CrossRef
  • When Being Lean Is Not Enough: The Metabolically Unhealthy Normal Weight Phenotype and Cardiometabolic Disease
    Dahyun Park, Min-Jeong Shin, Faidon Magkos
    CardioMetabolic Syndrome Journal.2024; 4(2): 57.     CrossRef
  • Association of anthropometric parameters as a risk factor for development of diabetic retinopathy in patients with diabetes mellitus
    Aditya Verma, Ashok Jha, Ahmed Roshdy Alagorie, Rishi Sharma
    Eye.2023; 37(2): 303.     CrossRef
  • From Metabolic Syndrome to Type 2 Diabetes in Youth
    Dario Iafusco, Roberto Franceschi, Alice Maguolo, Salvatore Guercio Nuzio, Antonino Crinò, Maurizio Delvecchio, Lorenzo Iughetti, Claudio Maffeis, Valeria Calcaterra, Melania Manco
    Children.2023; 10(3): 516.     CrossRef
  • Assessment of Metabolic Syndrome Risk Based on Body Size Phenotype in Korean Adults: Analysis of Community-based Cohort Data
    Ji Young Kim, Youngran Yang
    Research in Community and Public Health Nursing.2023; 34: 158.     CrossRef
  • Prevalence and factors related to the metabolically obese normalweight (MONW) phenotype: a review
    Edyta Suliga, Martyna Głuszek-Osuch, Stanisław Głuszek
    Medical Studies.2023; 39(1): 73.     CrossRef
  • New metabolic health definition might not be a reliable predictor for diabetes in the nonobese Chinese population
    Liying Li, Ziqiong Wang, Haiyan Ruan, Muxin Zhang, Linxia Zhou, Xin Wei, Ye Zhu, Jiafu Wei, Xiaoping Chen, Sen He
    Diabetes Research and Clinical Practice.2022; 184: 109213.     CrossRef
  • Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus?
    Qi Wu, Ming-Feng Xia, Xin Gao
    World Journal of Diabetes.2022; 13(2): 70.     CrossRef
  • Metabolically obese phenotype and its dynamic change are associated with increased carotid intima-media thickness: Results from a cohort study
    Liping Yang, Xue Li, Li Wang, Shan Xu, Yanmei Lou, Fulan Hu
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(9): 2238.     CrossRef
  • Obesity Metabolic Phenotype, Changes in Time and Risk of Diabetes Mellitus in an Observational Prospective Study on General Population
    Chan Yang, Xiaowei Liu, Yuanyuan Dang, Juan Li, Jingyun Jing, Di Tian, Jiangwei Qiu, Jiaxing Zhang, Ni Yan, Xiuying Liu, Yi Zhao, Yuhong Zhang
    International Journal of Public Health.2022;[Epub]     CrossRef
  • Implications of metabolic health status and obesity on the risk of kidney cancer: A nationwide population-based cohort study
    Yun Kyung Cho, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Metabolic health is a determining factor for incident colorectal cancer in the obese population: A nationwide population‐based cohort study
    Yun Kyung Cho, Jiwoo Lee, Hwi Seung Kim, Joong‐Yeol Park, Woo Je Lee, Ye‐Jee Kim, Chang Hee Jung
    Cancer Medicine.2021; 10(1): 220.     CrossRef
  • Cumulative Exposure to Metabolic Syndrome Components and the Risk of Dementia: A Nationwide Population-Based Study
    Yunjung Cho, Kyungdo Han, Da Hye Kim, Yong-Moon Park, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Endocrinology and Metabolism.2021; 36(2): 424.     CrossRef
  • Excessive Intake of High-Fructose Corn Syrup Drinks Induces Impaired Glucose Tolerance
    Hidemi Hattori, Yuma Hanai, Yuto Oshima, Hiroaki Kataoka, Nozomu Eto
    Biomedicines.2021; 9(5): 541.     CrossRef
  • The risk of Alzheimer’s disease according to dynamic changes in metabolic health and obesity: a nationwide population-based cohort study
    Yun Kyung Cho, Jiwoo Lee, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung
    Aging.2021; 13(13): 16974.     CrossRef
  • Metabolically healthy obesity: predictors of transformation to unhealthy phenotype in St Petersburg population (according to the ESSE-RF study)
    M. A. Boyarinova, O. P. Rotar, A. M. Erina, N. A. Paskar, A. S. Alieva, E. V. Moguchaia, E. P. Kolesova, A. O. Konradi
    "Arterial’naya Gipertenziya" ("Arterial Hypertension").2021; 27(3): 279.     CrossRef
  • Physiological and Lifestyle Traits of Metabolic Dysfunction in the Absence of Obesity
    Hanna Bjørk Klitgaard, Jesper Hoffmann Kilbak, Erica Arhnung Nozawa, Ann V. Seidel, Faidon Magkos
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity
    Tenzin D. Dagpo, Christopher J. Nolan, Viviane Delghingaro-Augusto
    Cells.2020; 9(7): 1596.     CrossRef
  • Prepregnancy smoking and the risk of gestational diabetes requiring insulin therapy
    Mee Kyoung Kim, Kyungdo Han, Sang Youn You, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Obesity with and without type 2 diabetes: are there differences in obesity history, lifestyle factors or concomitant pathology?
    E. A. Shestakova, Yu. I. Yashkov, O. Yu. Rebrova, M. V. Kats, M. D. Samsonova, I. I. Dedov
    Obesity and metabolism.2020; 17(4): 332.     CrossRef
Close layer
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
Nam Hoon Kim, Dong-Lim Kim, Kyeong Jin Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Endocrinol Metab. 2017;32(2):241-247.   Published online June 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.241
  • 10,110 View
  • 113 Download
  • 29 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   
Background

Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes.

Methods

In this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2α, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation.

Results

Both vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8±38.0 to 70.8±19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38±17.3 to 27.7±6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2α did not change after treatment in both groups.

Conclusion

In this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed.

Citations

Citations to this article as recorded by  
  • Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
    K.L. Jhaveri, N.M. Iyengar, N.C. Turner, H.S. Rugo, J. O’Shaughnessy, C.H. Barrios, G. Curigliano, F. André, S.-A. Im, M.D. Goncalves, M.E. Lacouture, P.A. Fasching, R. Leung
    ESMO Open.2026; 11(2): 105936.     CrossRef
  • Dietary effect on glucose homeostasis is modulated by a loss-of-function variant in the sucrase-isomaltase gene: a randomised, dietary crossover intervention in Inuit
    Ninna Senftleber, Marie Mathilde B. Christensen, Bendix Carstensen, Frederik Filip Stæger, Michael B. Frøst, Matthew P. Gillum, Torben Hansen, Marit E. Jørgensen
    Diabetologia.2026; 69(7): 2015.     CrossRef
  • Investigating the Genotoxic Potential of Pioglitazone in Hyperglycemic Conditions Using Chromosome Aberration and GADD45α Markers in TK6 Cells
    Darshan T. Valani, Dolatsinh B. Zala, Chetan K. Kajavadara, Laxit K. Bhatt, Hiren M. Patel, Rajesh Sundar, Mukul R. Jain
    Journal of Biochemical and Molecular Toxicology.2025;[Epub]     CrossRef
  • The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy
    Deyue Kong, Ziyang Shen, Lanlan Jiang, Xiaojing Xie, Rengna Yan, Ting Jing, Yun Hu, Jianhua Ma
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review
    Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar
    International Journal of Diabetes and Technology.2024; 3(2): 49.     CrossRef
  • Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities
    Yuyan Sun, Bing Lu, Yuanwen Hu, Yingqi Lv, Shao Zhong
    International Journal of General Medicine.2024; Volume 17: 4297.     CrossRef
  • Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus
    Alanood A. Howsawi, Manal M. Alem
    Scientific Reports.2024;[Epub]     CrossRef
  • What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
    Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa
    European Endocrinology.2023; 19(2): 4.     CrossRef
  • Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice
    Antonio Ceriello, Ali A. Rizvi, Manfredi Rizzo
    Advances in Therapy.2022; 39(1): 1.     CrossRef
  • Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study
    Abdulhamza Hmood, Mohammed Almasoody, Hameed Hussein Al-Jameel
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 506.     CrossRef
  • Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
    SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim
    Diabetes and Vascular Disease Research.2022;[Epub]     CrossRef
  • Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
    Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
    Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(5): 689.     CrossRef
  • Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study
    Manal M. Alem
    Heliyon.2022; 8(11): e11549.     CrossRef
  • Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy
    Rajesh Rajput, Suyasha Saini, Siddhant Rajput, Parankush Upadhyay
    Indian Journal of Endocrinology and Metabolism.2022; 26(6): 537.     CrossRef
  • Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
    Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2021; 45(3): 339.     CrossRef
  • Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications
    Bao Sun, Zhiying Luo, Jiecan Zhou
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review
    Anne-Esther Breyton, Stéphanie Lambert-Porcheron, Martine Laville, Sophie Vinoy, Julie-Anne Nazare
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects
    Sahar Hossam Elhini, Amal K. Hussien, Ahmed Abd Elsamie Omran, Asmaa A. Elsayed, Haitham saeed
    Clinical and Experimental Pharmacology and Physiology.2021; 48(12): 1589.     CrossRef
  • Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress
    Fariba Aghahoseini, Alireza Alihemmati, Leila Hosseini, Reza Badalzadeh
    Journal of Diabetes & Metabolic Disorders.2020; 19(2): 701.     CrossRef
  • Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes
    Kristina M. Utzschneider, Tonya N. Johnson, Kara L. Breymeyer, Lisa Bettcher, Daniel Raftery, Katherine M. Newton, Marian L. Neuhouser
    Journal of Diabetes and its Complications.2020; 34(8): 107586.     CrossRef
  • Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
    Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
    Diabetes, Obesity and Metabolism.2020; 22(2): 173.     CrossRef
  • Glycemic variability: adverse clinical outcomes and how to improve it?
    Zheng Zhou, Bao Sun, Shiqiong Huang, Chunsheng Zhu, Meng Bian
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
    Niki Katsiki, Ele Ferrannini
    Journal of Diabetes and its Complications.2020; 34(12): 107723.     CrossRef
  • Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study
    Suhua Li, Xixiang Tang, Yanting Luo, Bingyuan Wu, Zhuoshan Huang, Zexiong Li, Long Peng, Yesheng Ling, Jieming Zhu, Junlin Zhong, Jinlai Liu, Yanming Chen
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes
    Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li, Yanming Chen
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
    Xin Liu, Peng Men, Bo Wang, Gaojun Cai, Zhigang Zhao
    Lipids in Health and Disease.2019;[Epub]     CrossRef
  • Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
    Fahmida Alam, Md. Asiful Islam, Mafauzy Mohamed, Imran Ahmad, Mohammad Amjad Kamal, Richard Donnelly, Iskandar Idris, Siew Hua Gan
    Scientific Reports.2019;[Epub]     CrossRef
  • Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
    Subin Lee, Heeyoung Lee, Yoonhye Kim, EunYoung Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes
    Guillermo E. Umpierrez, Boris P. Kovatchev
    The American Journal of the Medical Sciences.2018; 356(6): 518.     CrossRef
Close layer
Case Reports
Adrenal gland
Pheochromocytoma with Markedly Abnormal Liver Function Tests and Severe Leukocytosis
Chai Ryoung Eun, Jae Hee Ahn, Ji A Seo, Nan Hee Kim
Endocrinol Metab. 2014;29(1):83-90.   Published online March 14, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.1.83
  • 9,566 View
  • 45 Download
  • 7 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   

Pheochromocytoma is a rare neuroendocrine tumor arising from the medulla of the adrenal glands, which causes an overproduction of catecholamines. The common symptoms are headache, palpitations, and sweating; however, various other clinical manifestations might also be present. Accurate diagnosis of pheochromocytoma is important because surgical treatment is usually successful, and associated clinical problems are reversible if treated early. A 49-year-old man with a history of uncontrolled hypertension and diabetes mellitus presented with chest pain, fever, and sweating. His liver function tests and white blood cell counts were markedly increased and his echocardiography results suggested stress-induced cardiomyopathy. His abdominal computed tomography showed a 5×5-cm-sized tumor in the left adrenal gland, and laboratory tests confirmed catecholamine overproduction. After surgical resection of the left adrenal gland, his liver function tests and white blood cell counts normalized, and echocardiography showed normal cardiac function. Moreover, his previous antihypertensive regimen was deescalated, and his previously uncontrolled blood glucose levels normalized without medication.

Citations

Citations to this article as recorded by  
  • Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches
    Andres M Vargas-Beltran, Samantha M Armendariz-Pineda, Froylan D Martínez-Sánchez, Carolina Martinez-Perez, Aldo Torre, Jacqueline Cordova-Gallardo
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Case Report: Elevated Aminotransferases and Altered Hepatic Perfusion due to Retroperitoneal Paraganglioma
    Gabriel de Magalhães Freitas, Caroline Tomas Heringer, Ébony Lima dos Santos, Carolina Oliveira de Souza, Silvia Regina Pereira Soares, Raul Carlos Wahle
    GE - Portuguese Journal of Gastroenterology.2025; : 1.     CrossRef
  • Pheochromocytoma-Induced Leukocytosis With Concurrent Severe Eosinophilia: A Case Report
    Nouf Alnaqeeb, Mohamed M Abd Elhamid, Ihab AImagdub, Randa Ali
    Cureus.2025;[Epub]     CrossRef
  • Liver Transplantation for Fulminant Hepatic Failure Precipitated by Pheochromocytoma Crisis in the Setting of Using Garcinia cambogia Weight Loss Supplement: A Case Report
    Motaz A Selim, Krystal Weierstahl, Calvin Eriksen, Terra Pearson, Harvey Woehlck
    Cureus.2023;[Epub]     CrossRef
  • Pheochromocytoma presenting with severe abdominal pain and abnormal liver enzymes
    Mhd Baraa Habib, Mohamed Abdelrazek, Sali Alatasi, Mouhand F. H. Mohamed, Hamda Ali, Mohamad Khair Hamad
    Clinical Case Reports.2021;[Epub]     CrossRef
  • A cardiogenic shock in PICU turned out to be a bilateral pheochromocytoma: A case report
    Jay Shah, Zinkal Patel, Shradha Patel, Amit Kumar
    Journal of Pediatric Critical Care.2021; 8(5): 255.     CrossRef
  • Endocrine Diseases and the Liver
    Miguel Malespin, Ammar Nassri
    Clinics in Liver Disease.2019; 23(2): 233.     CrossRef
  • Pheochromocytoma crisis presenting with hypotension, hemoptysis, and abnormal liver function
    Renhua Wu, Nanwei Tong, Xinlei Chen, Shishi Xu, Fang Zhang, Lizhi Tang, Yuwei Zhang
    Medicine.2018; 97(25): e11054.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
A Case of Multiple Osteoporotic Compression Fractures in Young Man with Budd-Chiari Syndrome.
Sun Hwa Kim, Tae Un Yang, Byeong Kwang Choi, Hye Jin Yoo, Ji A Seo, Kyung Mook Choi, Nan Hee Kim, Sin Gon Kim, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
Endocrinol Metab. 2012;27(4):334-339.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.334
  • 3,541 View
  • 32 Download
AbstractAbstract PDF
Osteoporosis in young men is extremely rare. In this report, we demonstrate a rare case of multiple vertebral fractures discovered in a young man with Budd-Chiari syndrome without prior history of trauma. A 29-year-old man was diagnosed as Budd-Chiari syndrome 12 years ago and underwent a mesocaval shunt to relieve the hepatic vein obstruction and was on warfarin therapy. He suffered from low back pain and it was not relieved by analgesics. A T-L spine X-ray revealed multiple compression fractures and the z-score at lumbar spine was -3.7 which is below the expected range for that age. The patient was treated with calcium, vitamin D and bisphosphonate, and showed clinical improvement. This case highlights the importance of the investigation for secondary osteoporosis in young adults with an underlying disease that alters bone metabolism.
Close layer
Original Article
Thyroid Dysfunction of North Korean Women Living in South Korea, Focusing on Subclinical Hypothyroidism.
Joo Hyung Kim, Sol Ah Park, Nam Hoon Kim, Jae Hee Ahn, Yoon Jung Kim, Myongjin Cho, Yoon Jung Lee, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim
Endocrinol Metab. 2012;27(3):200-207.   Published online September 19, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.3.200
  • 10,398 View
  • 32 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
Thyroid function depends on ethnic and environmental factors. North Korean refugees have the same genetic background as South Koreans, but they have been exposed to different environments. This study examines the prevalence and pattern of thyroid disorders in North Korean women living in South Korea, focusing on subclinical hypothyroidism (SCH). METHODS: The intended sample was a total of 327 North Korean women residing in Seoul. Health questionnaires and medical examinations, including serum thyrotropin (thyroid stimulating hormone, TSH), free thyroxine, and thyroid autoantibodies, were conducted. RESULTS: The prevalence of SCH was 9.4%. In logistic regression analysis, smoking, menopause, length of stay in South Korea, body mass index, history of thyroid disease, and metabolic syndrome were not associated with the risk of SCH. Whereas, the positivity of autoantibodies were associated with a high risk for SCH (odds ratio [OR], 4.840; 95% confidence interval [CI], 1.80-13.017; P = 0.002), and age was associated with a low risk for SCH (OR, 0.94; 95% CI, 0.888-0.994; P = 0.031). The serum TSH levels also decreased with increasing age, and in particular, there was significant difference between 30-39 years, and over 60 years (2.33 +/- 1.51 microIU/mL vs. 1.54 +/- 0.73 microIU/mL, P = 0.028). CONCLUSION: In North Korean women, the positivity of autoantibodies was associated with a high risk for SCH. But interestingly, a younger age was associated with a high risk for SCH. Considering that they suffered from severe famine at the period of growth, and this led to malnutrition, their thyroid dysfunction might be associated with the peculiar environment that they experienced.

Citations

Citations to this article as recorded by  
  • Systematic review of evidence on public health in the Democratic People’s Republic of Korea
    John J Park, Ah-Young Lim, Hyung-Soon Ahn, Andrew I Kim, Soyoung Choi, David HW Oh, Owen Lee-Park, Sharon Y Kim, Sun Jae Jung, Jesse B Bump, Rifat Atun, Hee Young Shin, Kee B Park
    BMJ Global Health.2019; 4(2): e001133.     CrossRef
  • Environmental Factors and Thyroid Dysfunction
    Hyun-Kyung Chung
    Endocrinology and Metabolism.2012; 27(3): 191.     CrossRef
Close layer
Case Reports
Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer.
Jae Hee Ahn, Sun Young Kim, Ye Ji Kim, Suk Young Lee, Jae Hyoung Lee, Seung Hun Kang, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
Endocrinol Metab. 2011;26(4):345-347.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.345
  • 6,409 View
  • 23 Download
  • 1 Crossref
AbstractAbstract PDF
Scanning with whole-body 131I scintigraphy after surgery has been a valuable diagnostic modality in the surveillance of patients with differentiated thyroid cancer. Radioiodine uptake is rarely observed in non-lactating breast tissue, which mimics thyroid cancer metastasis. We now report a case of a 45-year-old female thyroid cancer patient who underwent radioiodine therapy, and in whom breast uptake of radioiodine was observed on a post-therapy whole body scan. Her serum prolactin level was elevated to 328 ng/mL at the time of the radioiodine uptake, and the hyperprolactinemia was induced by her antipsychotic medications. Six months after she discontinued that medication, her serum prolactin level was normalized to 12.6 ng/mL and breast uptake of iodine was no longer present in a follow-up whole body scan.

Citations

Citations to this article as recorded by  
  • Incidental Findings of Intense Radioiodine Uptake in Struma Ovarii and Bilateral Nonlactating Breasts Simultaneously on Postablation 131I SPECT/CT for Papillary Thyroid Cancer
    Hye-kyung Shim, Mi Ra Kim
    Nuclear Medicine and Molecular Imaging.2016; 50(4): 353.     CrossRef
Close layer
Successful Localization of Distant Metastasis in Parathyroid Carcinoma Using Intraoperative Parathyroid Hormone Assay.
Ho Cheol Hong, Sun Won Kim, Tae Hyung Kim, In Hye Cha, Jae Hee Ahn, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Hyun Koo Kim, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Jae Bok Lee, Sei Hyun Baik, Dong Seop Choi
Endocrinol Metab. 2011;26(1):92-96.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.92
  • 4,004 View
  • 24 Download
  • 1 Crossref
AbstractAbstract PDF
Intra-operative parathyroid hormone (IOPTH) assay is a useful tool to confirm complete excision of all hyper-functioning parathyroid gland tissue. In this report, we describe a case with successful localization of distant metastasis in a patient with parathyroid carcinoma using the IOPTH assay. A 53-year-old man presented to our clinic with a serum calcium level of 11.8 mg/dL and an intact PTH level of 233.3 pg/mL. He had been treated for parathyroid carcinoma eleven years ago. Two suspected metastatic lesions were detected on the chest computed tomography. Due to the vastly different surgical field necessary to excise each lesion, we preferentially removed only one lesion and we monitored the other remaining suspected lesion without resection via IOPTH assay. Six months later, the patient's serum calcium and intact PTH levels remained within their normal ranges. To the best of our knowledge, this is the first case to effectively utilize IOPTH assay for the management of metastatic parathyroid carcinoma.

Citations

Citations to this article as recorded by  
  • The association of abdominal obesity, obesity and parathyroid hormone in Korean adults (aged≥50 years): The Korea National Health and Nutrition Survey, 2011
    Kyu Su Lee, Yo Sang Yoon, Hyun Yoon
    Journal of the Korea Academia-Industrial cooperation Society.2015; 16(6): 3882.     CrossRef
Close layer
A Case of Recurrent Ectopic Parathyroid Adenoma Developed 22 Years after the Initial Parathyroidectomy.
Yoon Jung Kim, Ji A Seo, Ji Mi Moon, Young Jin Seo, Hae Yoon Choi, Hye Sook Kim, Sin Gon Kim, Kyeung mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
J Korean Endocr Soc. 2009;24(4):260-264.   Published online December 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.4.260
  • 3,787 View
  • 29 Download
AbstractAbstract PDF
Persistent or recurrent primary hyperparathyroidism after initial parathyroid surgery occurs at rates of 1.5~10%. A single missed parathyroid adenoma accounts for the majority of persistent hyperparathyroidism, whereas metachronous parathyroid adenoma is a rare cause of recurrent hypercalcemia. We report a case of a 39-year-old female who presented with recurrent pancreatitis. She had symptoms of hyperparathyroidism such as hypercalcemia, hypophosphatemia, hypercalciuria, nephrocalcinosis, and osteoporosis. She had a 2-cm firm neck mass under the right submandibular area. She was diagnosed with primary hyperparathyroidism 22 years ago. At that time, the right upper and lower parathyroid glands were removed after exploration of all parathyroid glands, and a right upper parathyroid adenoma was diagnosed. Now, she had a second surgery to remove the right submandibular mass with intraoperative PTH monitoring, which was diagnosed as a parathyroid adenoma in an ectopic supernumerary parathyroid gland. Because of hungry bone syndrome, she received calcium carbonate replacement therapy and has no evidence of recurrence. Here, we report a recurrent parathyroid adenoma in the undescended, supernumerary parathyroid gland after a long interval from the initial surgery.
Close layer
A Case of Fulminant Type 1 Diabetes Mellitus Complicated with Ischemic Ileitis.
Se Won Oh, Ju Ri Park, Yun Jeong Lee, Hee Yeong Kim, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim
J Korean Endocr Soc. 2009;24(2):116-120.   Published online June 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.2.116
  • 3,052 View
  • 21 Download
AbstractAbstract PDF
Fulminant type 1 diabetes is characterized by diabetes with an abrupt onset, severe metabolic acidosis at diagnosis, a low HbA1c level and negativity for islet cell-related autoantibodies, and this illness has been classified as type 1B diabetes by the WHO. The prevalence of this disease is higher in Japan than any other country and recently, there have been an increasing number of such case reports in Korea. Genetic factors and environmental factors such as virus infection and an immune mechanism have been suggested as the mechanism of the pathophysiology, but this remains to be clarified.
Close layer
Normal Repetitive Pregnancies and Tumor Regression Induced by Low-Dose Bromocriptine in a Patient with Macroprolactinoma.
Hye Jung Choi, Jin Yong Park, Woo Seok Choi, Jong Gyu Song, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2009;24(1):42-46.   Published online March 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.1.42
  • 3,033 View
  • 19 Download
AbstractAbstract PDF
Prolactin-secreting adenomas are the most common pituitary tumors. Menstrual disturbances and infertility are the main complaints in women with prolactinoma. Dopaminergic agonists such as bromocriptine are well-established treatments for prolactinoma when pregnancy is desired. Pregnancy-related outcomes in macroprolactinoma are worse than those in microprolactinoma. In addition, symptomatic tumor expansion during pregnancy occurs in 30% of women with macroprolactinoma. Therefore, when women with macroprolactinoma are planning a pregnancy, serum prolactin level should be normalized and the tumor volume significantly reduced. On the other hand, a spontaneous regression of macroprolactinoma can occur after pregnancy. We report a case of macroprolactinoma showing significant tumor regression during repeated pregnancies and low dose bromocriptine treatment, with a literature review.
Close layer
Two Cases of Acromegaly with Empty Sella Syndrome Treated by Long-Acting Release Octreotide.
Dong Jin Kim, Young Jin Seo, Nam Hoon Kim, Hye Soo Chung, Chai Ryoung Eun, Hye Jung Choi, Hye Sook Kim, Sae Jeong Yang, Juri Park, Hye Jin Yoo, Soo Yeon Park, Yun Jeong Lee, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2007;22(2):135-141.   Published online April 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.2.135
  • 3,844 View
  • 37 Download
AbstractAbstract PDF
Two cases of typical acromegaly with empty sella syndrome presented to our institution. In the natural course of untreated pituitary adenoma, empty sella syndrome may result from necrosis by infarction or from hemorrhage of the pituitary gland. In our patients, the secretion of growth hormone continued in spite of the existence of empty sella syndrome. In one case, we confirmed the hypersecretion of growth hormone from sella by jugular vein sampling. Medical therapy with somatostatin analogue was attempted because there was no obvious mass in the sella. After 6~12 months of treatment with long-acting release octreotide, clinical features in our patients were improved, and the level of growth hormone and IGF-1 were also normalized.
Close layer
A Case of Sheehan's Syndrome Presenting Central Diabetes Insipidus.
Dong Jin Kim, Nan Hee Kim, Ju Ri Park, Sae Jeong Yang, Hye Suk Kim, Hye Jin Yoo, Soo Yeon Park, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2006;21(4):333-337.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.333
  • 3,793 View
  • 30 Download
AbstractAbstract PDF
Sheehan's syndrome occurs as a result of ischemic pituitary necrosis due to severe postpartum hemorrhage. The manifestations of this clinical syndrome are most often caused by a deficiency in the hormones produced by the anterior pituitary gland, whereas the neurohypophysis is usually preserved but can be involved in severe cases that manifest as diabetes insipidus. This is a report of Sheehan's syndrome that manifested with diabetes insipidus as presenting symptom 2 month's after delivery. The patient suffered massive bleeding, so received a blood transfusion. A combined pituitary stimulation and water deprivation test revealed deficiencies of not only anterior pituitary hormones, such as growth hormone and prolactin, but also of anti-diuretic hormone. We report this case, with a review of the literature.
Close layer
A Case of Primary Hyperparathyroidism Caused by Cystic Parathyroid Adenoma, Diagnosed during Intra-Operative PTH Monitoring.
Hye Jin Yoo, Nan Hee Kim, Soo Yeon Park, Dong Jin Kim, Sae Jeung Yang, Ju Ri Park, Hee Young Kim, Ji A Seo, Kye Won Lee, Sin Gon Kim, Kyung Mook Choi, Jae Bok Lee, Young Seok Lee, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2005;20(3):278-282.   Published online June 1, 2005
DOI: https://doi.org/10.3803/jkes.2005.20.3.278
  • 3,047 View
  • 27 Download
AbstractAbstract PDF
Primary hyperparathyroidism is the most frequent cause of hypercalcemia, and its prevalence is increasing due to the routine examination of serum calcium levels. Primary hyperparathyroidims is most commonly caused by an adenoma or hyperplasia of the parathyroid gland. A cystic parathyroid adenoma is an extremely rare cause of primary hyperparathyroidism. In our case, a-79-year old female presented with lower back pain and constipation. Her serum calcium, phosphate and immunoreactive parathyroid homone levels were 15.6, 1.8mg/dL and 371.8pg/mL, respectively. Neck CT revealed a cystic mass and a contour bulging heterogeneous mass in the left inferior right thyroid gland, respectively. These mass lesions were removed, and the intra-operative parathyroid hormone levels monitored, to confirm the complete resection. After removing the left cystic mass to the inferior thyroid, the serum calcium and immunoreactive parathyroid hormone levels quickly returned to normal. We report a case of primary hyperparathyroidism, caused by a cystic parathyroid adenoma, with a brief review of the literature
Close layer
Original Article
Hypopituitarism and Cardiovascular Complications.
Nan Hee Kim
J Korean Endocr Soc. 2004;19(4):300-302.   Published online August 1, 2004
  • 1,844 View
  • 17 Download
AbstractAbstract PDF
No abstract available.
Close layer
Case Report
A Case of Congenital Adrenal Hyperplasia due to 11beta-Hydroxylase Deficiency.
Ohk Hyun Ryu, Hye Jin Yoo, Soo Yeon Park, Soon Beom Kwon, Sang Soo Park, Hee Young Kim, Kye Won Lee, Ji A Seo, Jeong Heon Oh, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2004;19(1):58-63.   Published online February 1, 2004
  • 2,471 View
  • 49 Download
AbstractAbstract PDF
Congenital adrenal hyperplasia refers to a group of autosomal recessive disorders that is defective in the synthesis of cortisol. The enzymes most often affected are 21-hydroxylase and 11beta hydroxylase. The low levels of cortisol stimulate the pituitary gland to release ACTH. Chronic elevation of the ACTH level causes bilateral adrenal hyperplasia and a secondary increase in androgen formation. We examined a 19 year-old woman presented with clitoral hypertrophy and vaginal spotting. The subjects basal level of serum cortisol was low, but the serum levels of ACTH, 17a-hydroxyprogesterone, deoxy-corticosterone were elevated. The urinary excretions of 17-ketosteroids and 17-hydroxycorticosteroids were also increased. The karyotyping study and transrectal ultrasonography showed normal findings. The patient underwent clitoris reduction surgery and received hydrocortisone. To the best of our knowledge, this is the first case of 11beta-Hydroxylase deficiency in Korea.
Close layer
Original Articles
A Case of Multiple Endocrine Neoplasia 2A with Germ Line Mutation of RET Gene.
Hee Young Kim, Ji Yeon Lee, Sung Bum Kim, Kye Won Lee, Ji A Seo, Jeong Heon Oh, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
J Korean Endocr Soc. 2003;18(5):481-488.   Published online October 1, 2003
  • 2,028 View
  • 19 Download
AbstractAbstract PDF
Multiple endocrine neoplasia 2A (MEN 2A) is an autosomal dominantly inherited disease, composed of medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism. The activation of germ-line mutations in the RET proto-oncogene are responsible for MEN 2. The analysis of the RET mutations has replaced the measurement of the calcitonin level in the diagnosis of the MEN carrier state. Specific RET codon mutations correlate with the MEN 2 syndromic variant, the age at onset of the medullary thyroid carcinoma (MTC) and the aggressiveness of the MTC. Herein, our experience of a 47-year-old woman, who had a bilateral pheochromocytoma and MTC, and MEN 2A confirmed by the detection of an RET proto-oncogene mutation at axon 10 on codon 618, is reported. Her sister was found to have the same mutant gene. After a total thyroidectomy and bilateral adrenalectomy, the calcitonin and catecholamine levels were normalized, and the patient discharged without problems. This case is reported, with a review of the literature.
Close layer
Clinical Study of the Pheochromocytoma.
Dong Hyun Shin, Sin Gon Kim, Dong Rim Kim, Nan Hee Kim, Kyung Mook Choi, Saih Yun Baik, Dong Seop Choi, Sung Ock Suh
J Korean Endocr Soc. 2002;17(4):554-563.   Published online August 1, 2002
  • 2,020 View
  • 19 Download
AbstractAbstract PDF
BACKGROUND
Pheochromocytoma may arise within the adrenal medulla, or in other locations where sympathetic ganglia or chromaffin tissues are known to exist. Approximately 0.1% of hypertensive patients have pheochromocytoma. Most of this hypertension can be cured by surgical removal of the tumor, but lethal complication can develop if proper treatment is not prepared. Therefore, accurate diagnosis and preoperative preparation is very important. The objective of this study was to evaluate the clinical characteristics of pheochromocytoma and the blood pressure change following tumor removal. METHOD: The medical records of 45 patients [29 cases of intra-adrenal, 16 cases of extra-adrenal (paraganglioma)] diagnosed with of pheochromocytoma at Korea University Medical Center between 1991 and 2001 were reviewed. RESULTS: Twenty of the cases were male and 25 were female. The mean age of these patients was 43 years old. Hypertension, headaches, palpitations and impaired glucose tolerance were observed more frequently in cases of intra-adrenal tumor than in those of extra-adrenal. In the extra-adrenal group, abdominal pain, hypertension and nausea were more frequently observed. A biochemical study showed that the sensitivity of the test for catecholamines and metabolites in 24 hours urine was over 80%. For the localization of tumors we used abdominal CT and MIBG. The sensitivities of the CT and MIBG for the tumor localization were 97 and 91%, respectively. Blood pressures during the operations were effectively controlled by preoperative treatment with phenoxybenzamine (non-competitive, non-selective -adrenoreceptor antagonists). CONCLUSION: Surgical treatment cured 23 of the 30 cases of hypertension with pheochromocytoma. We have to take careful approaches in the care of the patient who may have pheochromocytoma, due to the various clinical signs and symptoms.
Close layer
Case Report
A Case of Malignant Pleural Effusion with Pleural Metastasis in a Patient with Papillary Thyroid Carcinoma.
Ju Young Kim, Dae Won Park, Jin O Na, Byoung Yeon Hwang, Dong Lim Kim, Dong Hyun Shin, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sung Jin Cho, Nan Hee Kim
J Korean Endocr Soc. 2002;17(2):269-274.   Published online April 1, 2002
  • 2,199 View
  • 26 Download
AbstractAbstract PDF
Papillary thyroid carcinomas comprise approximately 80 percent of all thyroid cancers, but haves a good prognosis, with overall survival rates at 10 years of about 80 to 95 percent. They spreads through the lymphatic system, and the lung is the most frequent metastasis site. If distant metastasis is present, the overall survival rate is about 40 percent. Although malignant pleural effusion, with pleural metastasis is a rare complication in patients with papillary thyroid carcinoma, the development of malignant pleural effusion is an extremely adverse prognostic indicator. We recently experienced a case of malignant pleural effusion with papillary thyroid carcinoma. A 54-year-old woman was admitted to the hospital because of dyspnea. A chest X-ray showed massive pleural effusion in the right hemithorax. Previously total thyroidectomy, and iodine-131 therapy had been performed, but a local recurrence and pulmonary metastasis developed 5 years later, accompanied by malignant pleural effusion with pleural metastasis. We performed diagnostic thoracentesis, which confirmed a metastatic papillary thyroid carcinoma. This patient was a rare case of paplillary thyroid carcinoma, in which the disease was represented by a rapid deterioration with malignant pleural effusion. So we report this case with a review of the literature.
Close layer
Original Article
The Association between CRP and the Metabolic Syndrome in Korean Adults.
Sin Gon Kim, Dong Lim Kim, Dong Hyun Shin, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2002;17(2):226-235.   Published online April 1, 2002
  • 2,242 View
  • 18 Download
AbstractAbstract PDF
BACKGROUND
Metabolic syndrome (MS) is characterized by insulin resistance accompanied by one or more of the following: obesity, hypertension, impaired glucose tolerance, low HDL cholesterol levels, and/or hypertriglyceridemia. However, the precise underlying pathogenic mechanism of MS is not known. Several recent reports have suggested a positive association between components of MS and markers of the acute-phase response, including C-reactive protein (CRP). These results imply that MS is accompanied by an ongoing inflammatory process. The purpose of our study was to evaluate the association between circulating levels of C-reactive protein, a sensitive systemic marker of inflammation, with components of metabolic syndrome in Korean adults. METHODS: A total of 1,461 subjects aged between 20 and 81 years, who visited the Health Management Center at Korea university between November 2000 and February 2001 were studied. We investigated the correlation between CRP levels and components of MS. The components of MS were categorized, and age-sex adjusted mean values of CRP calculated for the categorized components. The BMI was categorized into 5 classes, and the CRP levels examined according to their BMI class. In addition, subjects with a different number of the MS components were grouped as follows: group 1 for 0 components, group 2 for 1 components, group 3 for 2 components and group 4 for > or = 3 components, and the CRP levels calculated for each group. RESULTS: There were significant positive correlations of CRP levels with age, BMI, TG, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBS), uric acid, insulin,and homeostasis model assessment IR (HOMAIR). A significant inverse correlation was observed between CRP levels and serum HDL. From the multivariate analysis, age and BMI were significantly correlated with CRP levels. The means of the CRP for the categorized components of MS were significantly higher in the BMI categories: > or =25 for female/27 for male, TG > or =200 mg/dL, fasting plasma glucose > or =126 mg/dL and blood pressure > or =140/90 mmHg, and the CRP levels by BMI class were: 1.19 (BMI <18.5), 1.54 (BMI 18.5~22.9), 1.59 (BMI 23.0~24.9), 1.77 (BMI 25.0~29.9) and 2.07 (BMI >30.0) mg/L. Furthermore, the increase in the CRP levels in relation to the numbers of MS were 1.46 (group 1), 1.70 (group 2), 1.95 (group 3) and 2.11 mg/L (group 4) with statistical significance. CONCLUSION: The above data showed associations between the CRP levels and the different components of MS. This might suggest that MS in Koreans could be accompanied by a systemic inflammation response
Close layer
Case Reports
A Case of Parathyroid Cancer with a Local Metastatic Focus Revealed by 99mTc-sestamibi scan.
Soo Mi Kim, Shin Gon Kim, Ie Byung Park, Dong Hyun Shin, Jung Heon Oh, Nan Hee Kim, Se Hyun Baek, Seob Sub Choi, Jung Hwan Lee
J Korean Endocr Soc. 1997;12(4):627-632.   Published online January 1, 2001
  • 1,866 View
  • 16 Download
AbstractAbstract PDF
Carcinoma of the parathyroid gland is rare, comprising only 0.1% to 5% of all patients with primary hyperparathyroidism. It presents with severe hypercalcemia, bone disease, palpable neck mass, renal involvement and etc. Since the initial operation offers the best chance for cure, preoperative localization and intraoperative recognition of parathyroid cancer are essential. Recently parathyroid imaging has been described with 99mTc-sestamibi as an alternative to 201Tl. This newer agent has many physical and dosirnetric advantages and represents higher detection sensitivity than 201Tl-99mTc subtraction scan. We experienced a 41-year-old man presenting with recurrent hyperparathyroidism in spite of 2 previous operations. In preoperative localization, there was no abnormal uptake in 201Tl-99mTc subtraction scan but 99mTc-sestamibi scan revealed metastatic foci on right cervical area. He was successfully treated with modified radical neck dissection.
Close layer
A Case of Afrenocortical Carcinoma Associated with Multiple Paraganglioma.
Kyung Mook Choi, Jeong Heon Oh, Nan Hee Kim, Yong Hyun Kim, Ae Ree Kim, Chul Hwan Kim, Sang Jin Kim, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 1999;14(3):599-604.   Published online January 1, 2001
  • 1,947 View
  • 20 Download
AbstractAbstract PDF
Simultaneous oceurrence of adrenocortical tumor and pheochromocytoma is extremely rare. Coexistence of adrenal tumor and pheochromocytoma was first reported by Cope in 1952 and some other cases were reported after that. But there was no report about coexistence of adrenocortical carcinoma and paragangliomas. Recently, we experienced a case of adrenocortical carcinoma associated with multiple paragangliomas. A 35-year-old woman was admitted to the hospital because of left upper abdominal pain. A palm-sized fum tender mass was palpated at left upper quadrant. Hormonal studies revealed pheochromocytomas feature. Fmergency operation was performed because of the possibility of intemal hemorrhage of the tumor. Operator found 10 cm sized mass in left adrenal area and also the other 5 small tumors adjacent to IVC. Pathologic report revealed that adrenal mass was adrenocortical carcinoma with hemorrhagic necrosis and tumors adjacent to IVC were paragangliomas. This patient was the first case of adrenocortical carcinoma with multiple paragangliomas in the world. So we report this case with a review of literature.
Close layer
A Case of Insulinoma which was treated by Laparoscopic Enucleation.
Ie Byung Park, Young Jae Oh, Jung Heon Oh, Nan Hee Kim, Sang Jin Kim, Se Hyun Baek, Seob Sub Choi, Sung Ok Seo, Min Kyung Kim
J Korean Endocr Soc. 1998;13(4):665-669.   Published online January 1, 2001
  • 1,846 View
  • 16 Download
AbstractAbstract PDF
Insulinoma is a functional endocrine tumor arising from the beta cells of islets of Langerhans of pancreas. The only effective treatment of insulinoma was surgical removal of the tumor. Recently, laparoscopic surgery for islet cell tumors of the pancreas is introduced. Laparoscopic enucleation or resection of benign islet tumors results in a shorter hospital recovery and is a good alternative to open surgery We report a case of insulinoma that was treated sucessfully by laparoscopic enucleation.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP